Skip to content
10-Q

Quarterly Report

Arcus Biosciences, Inc. RCUS

0001724521-26-000034

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 125.77M sh
Shares Diluted Q1 2026 · Mar 31, 2026 125.4M sh
Shares Diluted Q1 2026 · Mar 31, 2025 98.4M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $1M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$138M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$132M
Long Term Debt Q1 2026 · Mar 31, 2026 $100M
Long Term Debt Q1 2026 · Dec 31, 2025 $99M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $201M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $222M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $192M
Stockholders Equity Q1 2026 · Mar 31, 2026 $524M
Stockholders Equity Q1 2026 · Dec 31, 2025 $631M
Stockholders Equity Q1 2026 · Mar 31, 2025 $531M
Stockholders Equity Q1 2026 · Dec 31, 2024 $485M
Current Liabilities Q1 2026 · Mar 31, 2026 $209M
Current Liabilities Q1 2026 · Dec 31, 2025 $231M
Current Assets Q1 2026 · Mar 31, 2026 $844M
Current Assets Q1 2026 · Dec 31, 2025 $1.01B
Total Assets Q1 2026 · Mar 31, 2026 $997M
Total Assets Q1 2026 · Dec 31, 2025 $1.14B
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.02
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.14
Eps Basic Q1 2026 · Mar 31, 2026 −$1.02
Eps Basic Q1 2026 · Mar 31, 2025 −$1.14
Sga Expense Q1 2026 · Mar 31, 2026 $29M
Sga Expense Q1 2026 · Mar 31, 2025 $28M
Rd Expense Q1 2026 · Mar 31, 2026 $122M
Rd Expense Q1 2026 · Mar 31, 2025 $122M
Net Income Q1 2026 · Mar 31, 2026 −$128M
Net Income Q1 2026 · Mar 31, 2025 −$112M
Operating Income Q1 2026 · Mar 31, 2026 −$134M
Operating Income Q1 2026 · Mar 31, 2025 −$122M
Revenue Q1 2026 · Mar 31, 2026 $7M
Revenue Q1 2026 · Mar 31, 2025 $8M